HHHelen Hwang

Helen Hwang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Helen Hwang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal brain morphometry in Parkinson's disease clinical subtypes: Distinct signatures forecast behavioral change within subtypes

    by Abdulmunaim M. Eid, Sarah Grossen, Aaron Tanenbaum, Helen Hwang, Therese V. Cash, Erin E. Franklin, Baijayanta Maiti, Erin R. Foster, Christina N. Lessov-Schlaggar, Richard J. Perrin, et al.


  • Open Access

    Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth

    by Helen Hwang, Dhruva D. Dhavale, Sarah J. Wang, Ajay Guduputi, John M. Beale, Nigel J. Cairns, Paul T. Kotzbauer

    Alpha-synuclein (asyn) fibril accumulation is the defining feature of Parkinson disease and is a target for disease-modifying treatments. One therapeutic strategy to reduce fibril accumulation is inhibition of asyn fibril growth. We developed a sensitive fluorescence-based fibril growth assay to screen for small molecule inhibitors. After validating the inhibition assay using a previously identified inhibitor, epigallocatechin-3-gallate, we identified compound 1 as a lead for inhibition of fibril growth. We analysed structure-activity relationships with analogs of 1 to optimize inhibition potency. Our results identified two dimethoxyphenyl piperazine analogs with more potent inhibition of in-vitro assembled fibrils, which were further validated with orthogonal assays including kinetic measurements of fibril concentration with Thioflavin T. These analogs also inhibited the growth of asyn fibrils amplified from Lewy Body Disease brain tissue, further validating the inhibitor screening assay. Molecular docking studies indicate that these compounds can bind to the fibril ends, suggesting a potential capping mechanism through which these compounds inhibit the sequential association of monomeric asyn required for fibril growth.

  • Open Access

    Use of Amplified Lewy Body Dementia Fibrils and Autoradiography to Characterize Binding of Radioligand Tg-1-90B to Alpha-Synuclein Fibrils in Postmortem Brain Tissue

    by Jennifer Y. O’shea, Dhruva D. Dhavale, Helen Hwang, Zachary Smith, Thomas J. A. Graham, Robert H. Mach, Paul T. Kotzbauer

    Parkinson’s disease (PD) and Lewy Body Dementia (LBD) are defined by accumulation of alpha-synuclein (Asyn) fibrils within Lewy bodies (LBs) and Lewy neurites (LNs). The development of a Positron Emission Tomography (PET) tracer for quantifying Asyn fibrils would improve diagnostic accuracy and provide a biomarker for disease progression. We previously described radioligand [3H]Tg-1-90B, which binds to in vitro Asyn fibrils (PDB 2N0A) via interactions with residues Y39, S42 and K44. Here, we performed molecular docking studies with Tg1-90B and PD/LBD Asyn fibrils (PDB 8A9L), which predicts interactions with residues Y39 and K43 in a structurally distinct binding site. In radioligand binding assays, Tg-1-90B has moderate to high affinity (Kd 17.5 nM) for amplified LBD fibrils (PDB 8FPT), whose protofilament fold is highly similar to PD/LBD fibrils (PBD 8A9L). Autoradiography confirmed binding of [3H]Tg-1-90B to LBs in PD brain tissue. However, Tg-1-90B also binds to amyloid-beta fibrils in Alzheimer’s disease (AD) tissue, indicating insufficient selectivity for Asyn fibrils. These results indicate that Tg-1-90B binds to Asyn fibrils in PD tissue but needs further structural optimization. Binding assays with amplified LBD fibrils and autoradiography with postmortem PD tissue can guide further development of Asyn fibril PET ligands for PD/LBD.


  • Open Access

    Identification of Small Molecule Dimethyoxyphenyl Piperazine Inhibitors of Alpha-Synuclein Fibril Growth

    by Helen Hwang, Dhruva D. Dhavale, Sarah J. Wang, John M. Beale, Nigel J. Cairns, Paul T. Kotzbauer

    Identification of Small Molecule Dimethyoxyphenol Piperazine Inhibitors of Alpha-Synuclein Fibril Growth Alpha-synuclein (asyn) fibril accumulation is the defining feature of Parkinson disease and is a target for disease-modifying treatments. One therapeutic strategy to reduce fibril accumulation is inhibition of asyn fibril growth. We developed a sensitive fluorescence-based fibril growth assay to screen for small molecule inhibitors. After validating the inhibition assay using a previously identified inhibitor, epigallocatechin-3-gallate, we identified compound 1 as a lead for inhibition of fibril growth. We analysed structure-activity relationships with analogs of 1 to optimize inhibition potency. Our results identified two dimethoxyphenyl piperazine analogs with more potent inhibition of in-vitro assembled fibrils. These analogs also inhibited the growth of asyn fibrils amplified from Lewy Body Disease brain tissue, further validating the inhibitor screening assay. Molecular docking studies indicate that these compounds can bind to the fibril ends, suggesting a potential capping mechanism through which these compounds inhibit the sequential association of monomeric asyn required for fibril growth.

  • Open Access

    Case Series: Dystonia with multiple sclerosis and neuromyelitis optica

    by Helen Hwang, Victoria A. Levasseur, Joel S. Perlmutter

    Dystonia is an uncommon complication of relapsing-remitting multiple sclerosis (MS) and related disorders. The types of dystonia described associated with MS are heterogenous, and the relationship between dystonia and MS remains unclear. Moreover, the anatomical correspondence between MS lesions and the site of dystonia has not been determined. Onset, treatment response, and outcomes of dystonia associated with MS still remain largely uncharacterized. Here, we report a case series of 14 patients with dystonia affecting different body parts in people with MS and neuromyelitis optica (NMO). We characterize the brain regions associated with this form of secondary dystonia and the response to botulinum toxin injections.

  • Open Access

    Prolonged response of recurrent IDH -wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab

    by Helen Hwang, Jiayi Huang, Karam Khaddour, Omar H Butt, George Ansstas, Jie Chen, Ruth Gn Katumba, Albert H Kim, Eric C Leuthardt, Jian L Campian

    Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged ...


  • Open Access

    Managing Advanced Parkinson Disease

    by Helen Hwang, Scott A. Norris

    Advanced Parkinson disease (PD) is associated with treatment-related motor fluctuations and reduced ability to perform activities of daily living. Progression of non-motor symptoms and medication-induced adverse effects complicate focused approach to motor symptom management, frequently accelerating reduced quality of life. It is thus critical for clinicians to consider disease progression versus therapeutic contributions when balancing management decisions. Such an approach requires careful recognition of inflection points resulting from therapeutic decisions and should prompt consideration of reduced pharmacologic burden and increased reliance on non-pharmacologic strategies in advanced disease. The successful approach to advanced PD requires a multidisciplinary effort focused on improving the patient’s and family’s quality of life, sometimes requiring sacrifice of motor symptom benefit. Here, we emphasize management strategies in advanced PD, focusing on the need to balance the therapeutic approach across advancing motor symptoms, progressive non-motor features, and potential pharmacologic adverse effects.


  • Feature Profile Evolution Simulation Using a Level Set Method

    by Helen H. Hwang, T. R. Govindan, M. Meyyappan

    A level set formulation is used to simulate profile evolution in etching and deposition processes. This approach, an alternative to string algorithms to track a moving front, is coupled to a model that computes etch rates based on first principles. Results are presented for silicon etching in a chlorine plasma. Etch profiles for various ratios of neutral to ion flux, ion anisotropy parameters, trench widths, and mask thickness are presented. Simulations capture the reactive ion etching lag effect and shadowing effects due to mask thickness. © 1999 The Electrochemical Society. All rights reserved.